This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The cGAS STING pathway market is estimated to be worth $305 million in 2020 and is expected to grow at CAGR of 25% during the forecast period. In recent years, promising insights from research on the cytosolic DNA sensing (cGAS -STING) pathway has caused a lot of enthusiasm within medical science community. In fact, more than 50 experimental interventions based on this relatively novel concept are currently being developed for the treatment of oncological, autoimmune and inflammatory disorders....

The single cell sequencing market is estimated to be worth $1,387 million in 2020 and is expected to grow at compounded annual growth rate (CAGR) of 15% during the forecast period. Over the years, technological advances in the field of genomics have enabled pharma companies to adopt a more personalized and targeted approach to drug / therapy development. In fact, the cost of sequencing a single genome has dropped from USD ~3 billion (Human Genome Project 1990) to USD 1,000 (Illumina sequencing k...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The intranasal and inhaled drug development market is estimated to be worth $5.5 billion in 2020 and is expected to grow at CAGR of 7.6% during the forecast period. Over the past few decades, the prevalence of respiratory disorders has been increasing at an alarming rate. In fact, each year around 7 million deaths are attributed to respiratory disorders caused by air pollution, worldwide. It is also important to note that, as of April 2020, an estimated 330 million individuals are suffering fro...

Our estimates suggest that the global AI in energy market is likely to be worth USD 2.1 billion in 2020, and this value is projected to reach USD 30.8 billion by 2030, growing at a CAGR of 30.6%.

The non invasive diagnostics market for fibrotic diseases is estimated to be worth $1.6 billion in 2020 and is expected to grow at CAGR of 10% during the forecast period. Notably, with non-alcoholic fatty liver disease (NAFLD) (subsequently progressing to nonalcoholic steatohepatitis / NASH drugs) being the primary cause of liver disease, nearly 4.5 million adults in the US have been diagnosed with this condition in 2018. Similarly, idiopathic pulmonary fibrosis (IPF) is a chronic, progressive,...

The non invasive neurostimulation devices market is estimated to be worth $1 billion in 2020 and is expected to grow at CAGR of 11% during the forecast period. Over the past few decades, the prevalence of neurological disorders has been increasing at an alarming rate, particularly among the geriatric population across the world. In fact, nearly 1 million Americans are reported to be living with Parkinson

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The AI in medical imaging market size is projected to grow from $1.75 billion in 2024 to $8.56 billion by 2030, growing at a CAGR of 30% during the forecast period from 2024 to 2030. Notably, in situations characterized by low physician / pathologist to patient ratios, the conventional mode of operation is rendered inadequate. Experts have predicted a shortage of 10,000 to 40,000 physicians, by 2030, in the US alone. Over time, various industry stakeholders have designed proprietary deep learnin...

The global diabetes drug delivery devices market, valued at USD 17 billion in 2025, is projected to reach USD 18 billion in 2026 and USD 31 billion by 2030, with a 14.1% CAGR during the forecast period 2026 to 2030. It is worth mentioning that according to the WHO, more than 400 million individuals across the world are currently suffering from diabetes; this number is estimated to reach over 570 million by 2030. Further, in patients with diabetes, glycemic control is required multiple times i...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The drug repurposing market is estimated to be worth $313 million in 2020 and is expected to grow at CAGR of 14.7% during the forecast period. Of late, the repurposing of marketed / shelved / pipeline candidates for the treatment of diseases different from what they were originally developed for, has emerged as a viable business strategy. In fact, of 28 drugs (including both novel and repurposed) approved by the USFDA in the first quarter of 2020, 12 were repurposed drugs. Further, it is estimat...

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment about the drug

One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for Pemphigus vulgaris, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of the forecasted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2020-2030. It features an in-depth analysis, highlighting the current treatment pract...

This report provides an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Neuromyelitis optica. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the drug